Rate of Cancer of Granular Mixed Laterally Spreading Tumors (GM-LST)
NCT03836131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2020-02-12
Summary
Colorectal cancer (CRC) is the third most common cancer in men and the second in women worldwide, with 1.65 million new cases and almost 835,000 deaths in 2015. CRC is still a major cause of mortality associated with cancer, although the wide spread of the screening program has led to a reduction in the mortality rate compared to the last decades.
CRCs derive from precancerous lesions that may be polypoid or non-polypoid according to the Paris classification. Thus, resection in an early stage could led to a CRC mortality reduction.
Laterally spreading tumors (LST) are non-polypoid lesions of at least 1 cm in diameter that have lateral growth rather than upward or downward growth.
The prevalence of LSTs ranges from 1 to 6% of all colorectal lesions. LSTs can be divided into two groups: granular LSTs, which include homogeneous and granular mixed forms and non-granular (NG) LSTs, which include pseudo-depressed and flat-elevated forms.
Histologically, 90% of LSTs are adenomas and having a low incidence of invasive neoplasia, these lesions can be removed endoscopically.
However, as evidenced by a recent meta-analysis published by Bogie Roel MM et al on Endoscopy, the type of LST and the distal or proximal colonic localization could represent predictors of submucosal invasion and could simplify the therapeutic decision for the removal of these lesions. GM-LSTs and pseudo-depressed NG-LSTs predominantly localize in the distal portion of the colon and have a submucosal invasion rate of 10,5% and 31,6% respectively.
LSTs can be removed both through endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). The main limitation of EMR is that large lesions require a piecemeal approach, resulting in a non-optimal histological evaluation and a high risk of recurrence. ESD instead allows a higher rate of en bloc resections, thus resulting more curative and reducing the risk of having partial and incomplete resections, which can lead to disease recurrence/non curative resection.
LST-GM are characterized by the presence of a granular appearance with a main nodule and represent approximately 1/4 of the LSTs. There are no guidelines indicating the proper resective technique of these lesions.
The European Society of Gastrointestinal Endoscopy (ESGE) suggests to consider ESD for the removal of colorectal lesions that are \> 20 mm in size, with a depressed and irregular morphology or a non-granular surface pattern, as these lesions have a high probability of having a limited submucosal invasion. Moreover ESD can be used to treat lesions that cannot be completely removed with standard polypectomy or EMR.
The investigators propose to perform a multicenter retrospective observational study to define the percentage of cancer in patients with GM-LSTs treated with endoscopic resection in order to evaluate the correlation between pre-resection and post-resection characteristics, defining the best therapeutic approach (en bloc or piecemeal) and avoiding incomplete endoscopic resections or unnecessary surgical procedures.
Conditions
Sponsors & Collaborators
-
Istituto Clinico Humanitas
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-31
- Primary Completion
- 2020-01-31
- Completion
- 2020-01-31
Countries
- Italy
Study Locations
More Related Trials
-
Dissecting the Biology of Early-onset Colorectal Cancer
NCT05916443 ·Status: UNKNOWN
-
Incidence, Risk Factor, Treatment and Overall Survival of Locoregionally Recurrent Colon Cancer
NCT05475288 ·Status: COMPLETED
-
Multistate Relative Survival Model
NCT02894801 ·Status: COMPLETED
-
Microbiome Testing for the Screening of Colorectal Cancer
NCT06588166 ·Status: RECRUITING
-
A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients
NCT06326879 ·Status: RECRUITING
-
Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms
NCT05038358 ·Status: RECRUITING
-
Characterization of Brazilian Colorectal Cancer Screening Population
NCT03355391 ·Status: UNKNOWN
-
Dietary Patterns, Metabolomics and Colorectal Cancer Risk
NCT03364582 ·Status: COMPLETED
-
Are Sporadic Colorectal Cancers in Young Distinct From Elderly?
NCT05601609 ·Status: COMPLETED
-
Alcohol Intake, Alcohol Metabolizing Enzymes Gene Polymorphisms and the Risk of Colorectal Cancer
NCT03155542 ·Status: COMPLETED
-
Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients
NCT01877135 ·Status: UNKNOWN
-
Retrospective Study on Epidemiology of Colorectal Lesions
NCT03035136 ·Status: COMPLETED
-
Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic Cancer
NCT05793775 ·Status: COMPLETED
-
A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence
NCT02005913 ·Status: UNKNOWN
-
Impact of EDUcation Strategy on Patients With COLorectal CANCER or Advanced Adenoma in the Detection of Colorectal Cancer of Their First-degree Relatives
NCT03084133 ·Status: COMPLETED ·Phase: NA
-
FOcUs on Colorectal CAncer oUtcomes: Long-Term Study
NCT03965325 ·Status: COMPLETED
-
Do Patients With Colorectal Cancer Understand That Their Family is at Risk?
NCT00145860 ·Status: TERMINATED
-
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
NCT01428752 ·Status: UNKNOWN
-
Treatment and Outcomes of Stage III Colon Cancer in Patients 80 Years of Age and Older
NCT04526314 ·Status: COMPLETED
-
Does Numerical And Pictorial Information On Risk And Benefit Affects The Uptake Of Colorectal Cancer Screening?
NCT01250015 ·Status: COMPLETED
-
Quantifying Micro RNA Levels of Colon
NCT01712958 ·Status: UNKNOWN
-
Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening
NCT02038283 ·Status: COMPLETED
-
Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers
NCT02557061 ·Status: COMPLETED ·Phase: NA
-
Personalised and Gamification-based Decision Aid (DA): a Randomized Controlled Pilot Study About Colorectal Cancer (CRC) Screening
NCT07269028 ·Status: COMPLETED ·Phase: NA
-
Personalizing Colorectal Cancer Medicine (ImmuCol2)
NCT02274753 ·Status: UNKNOWN